Guidelines: DEGRO Guidelines (Germany): Difference between revisions
m (Update categories.) |
m (Update categories.) |
||
| Line 50: | Line 50: | ||
<span style="display:none">hasCancerType::C76-C80: Cancers of unknown or unspecified areas</span> | <span style="display:none">hasCancerType::C76-C80: Cancers of unknown or unspecified areas</span> | ||
<span style="display:none">isPracticeGuideline</span> | <span style="display:none">isPracticeGuideline</span> | ||
<span style="display:none">hasCancerType::C00-D48: All neoplasms</span> | |||
<span style="display:none">hasCancerType::C00-C97: All cancer types</span> | |||
Revision as of 11:22, 6 December 2025
Go back to Germany page
Primary purpose: To establish evidence-based practices for the use of stereotactic radiotherapy and radiosurgery.
Sponsor, manager or home institution: DEGRO.
Type of information: Detailed protocols and evidence-based recommendations for conducting stereotactic radiotherapy and radiosurgery, focusing on specific conditions like brain metastases, early-stage non-small cell lung cancer (NSCLC), primary and secondary liver cancer, renal and pancreatic cancer, and ventricular tachycardia. These include best practices for treatment planning, dosing, patient selection, and outcomes assessment. medical procedures; diagnosis. Click here to learn more.
Cancer areas of interest: C15-C26: Digestive system cancers; C30-C39: Lung/chest cancers; C69-C72: Eye and brain cancer; C64-C68: Urinary system cancers; C76-C80: Cancers of unknown or unspecified areas. Click here to learn more.
Access to information: Click here to access.